Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.15 is 179% above its 5-year average of -0.19, around the middle of its 5-year range (-0.79–1.34).
As of the fiscal period ended Tuesday, June 30, 2026. 33.21% above its 12-month average of 0.11.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.15.
DEBT TO EQUITY RATIO
0.15
DEBT TO EQUITY RATIO AVG TTM
0.11
DEBT TO EQUITY RATIO AVG 3Y
0.10
DEBT TO EQUITY RATIO AVG 5Y
-0.19
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+33.21%
CURRENT VS 3Y AVG
+54.37%
CURRENT VS 5Y AVG
+178.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
+15.53%
vs the sector median at left
Genelux Corporation
Market Cap
$114.79M
Debt to Equity Ratio
0.15
TTM Avg
0.11
3Y Avg
0.10
5Y Avg
-0.19
Market Cap
$116.54M
Debt to Equity Ratio
0.27
TTM Avg
0.16
3Y Avg
0.12
5Y Avg
0.10
Market Cap
$116.57M
Debt to Equity Ratio
N/A
TTM Avg
0.12
3Y Avg
0.14
5Y Avg
0.21
Market Cap
$116.83M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$112.36M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$112.52M
Debt to Equity Ratio
2.28
TTM Avg
3.15
3Y Avg
2.13
5Y Avg
1.28
Market Cap
$110.73M
Debt to Equity Ratio
0.27
TTM Avg
0.66
3Y Avg
0.63
5Y Avg
0.55
Market Cap
$120.24M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $114.79M | 0.15 | 0.11 | 0.10 | -0.19 |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | 0.27 | 0.16 | 0.12 | 0.10 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | N/A | 0.12 | 0.14 | 0.21 |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 0.11 | 0.10 | 0.08 | 0.09 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.83M | 0.00 | 0.01 | 0.01 | 0.00 |
| Coya Therapeutics, Inc. (COYA)vs › | $112.36M | 0.00 | 0.00 | 0.00 | 0.00 |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | 2.28 | 3.15 | 2.13 | 1.28 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $110.73M | 0.27 | 0.66 | 0.63 | 0.55 |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.24M | 0.02 | 0.02 | 0.02 | 0.01 |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | 0.14 | 0.14 | 0.16 | 0.14 |
Debt/Equity
0.15
Current Ratio
2.39
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.15 |
| 2026-03-31 | 0.11 |
| 2025-12-31 | 0.15 |
| 2025-09-30 | 0.09 |
| 2025-06-30 | 0.07 |
| 2025-03-31 | 0.06 |
| 2024-12-31 | 0.07 |
| 2024-09-30 | 0.06 |
| 2024-06-30 | 0.06 |
| 2024-03-31 | 0.16 |
| 2023-12-31 | 0.13 |
| 2023-09-30 | 0.08 |
| 2023-06-30 | 0.08 |
| 2023-03-31 | 1.34 |
| 2022-12-31 | -0.74 |
| 2022-09-30 | -0.79 |
| 2022-06-30 | -0.65 |
| 2022-03-31 | -0.69 |
| 2021-12-31 | -0.76 |
| 2021-09-30 | -0.73 |
| 2021-06-30 | -0.73 |
| 2021-03-31 | -1.03 |
| 2020-12-31 | -1.15 |
| 2020-09-30 | -1.12 |
| 2020-06-30 | -1.12 |
| 2020-03-31 | 0.00 |
